Alcoholic & MASLD Liver Disease

Meet the patient

It is 3am. A 48-year-old man is wheeled in deeply jaundiced, nauseated, with a tender enlarged liver edge and a low-grade fever. His partner says he drinks half a bottle of whisky a day, and has for years. Bloods: AST 210, ALT 70, bilirubin 280, INR 2.1, MCV 108. The registrar fires three questions you must answer before sunrise — is this alcoholic hepatitis, and how severe? What is the first drug you reach for (and what must you exclude first)? And when do you stop it?[1]

Hold that picture. Every number on this page is built to answer him.[1]

Two insults, one pathway

Alcohol-related liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are the two commonest chronic liver diseases on the planet — and they share a single pipeline. The pipeline runs steatosis (fat) to steatohepatitis (fat plus inflammation and ballooning) to fibrosis to cirrhosis to hepatocellular carcinoma. What differs is the tap you turn off at the top: ethanol for ALD, metabolic overload for MASLD. Internalise that one sentence now.[1][2]

The topic mantra: two insults, one pathway. Stop the insult early and the disease regresses; let it run and stellate-cell fibrosis becomes irreversible.[1]

The 2023 rename — and why it is not cosmetic. A multisociety Delphi consensus retired NAFLD for MASLD (metabolic dysfunction-associated steatotic liver disease) and NASH for MASH.[2] The old name defined the disease by what the patient was not doing (not drinking); the new name anchors it to what they are doing (metabolic dysfunction). It strips the stigma of "fatty", harmonises paediatric and adult language, and carves out a new box — MetALD — for the patient in whom both alcohol and metabolic disease contribute substantially (drinking above the MASLD threshold but not enough to call ALD the sole cause).

MASLD needs steatosis plus at least one metabolic box ticked: overweight or obesity (BMI over 25, or over 23 in South Asians), type 2 diabetes, or at least two of — waist high, blood pressure at least 130/85 (or treated), triglycerides at least 1.7 mmol/L (or treated), HDL under 1.0 mmol/L in men and 1.3 mmol/L in women (or treated), prediabetes or fasting glucose at least 5.6 mmol/L, HOMA-IR at least 2.5, or hs-CRP over 2 mg/L.[2]

The alcohol ceiling for MASLD is under 20 g/day in women and under 30 g/day in men (about 1.5 to 2 standard drinks). Drink more than that and the diagnosis is ALD; sit in the overlap and it is MetALD.[2]

ALD is a spectrum of its own. At the benign end sits alcohol-associated steatosis — asymptomatic, reversible with abstinence. In the middle is alcoholic steatohepatitis (ASH), latent inflammation you only see on biopsy. At the sharp end is alcoholic hepatitis (AH): the clinically overt, inflammatory syndrome of new jaundice in a heavy drinker, with anorexia, tender hepatomegaly, fever and leucocytosis, and biochemically AST over ALT (ratio over 2), both typically under 300 U/L. AH is what kills people in weeks; the rest grumble for years. By the bye, cirrhosis takes its name from the Greek kirrhos, tawny-orange — the colour of the fatty, nodular liver at autopsy.[1]

Two parallel spectra

Classify along two axes: the aetiological driver, and the histological stage. The driver tells you which tap to turn off; the stage tells you how worried to be. Everything else is detail.[1]

[1]

The shared histology is staged F0 (no fibrosis) through F4 (cirrhosis), graded by the SAF (Steatosis-Activity-Fibrosis) score or, for MASLD, the NAS (NAFLD Activity Score). F0 to F3 is "compensated"; F4 is "cirrhotic". That single line decides who gets variceal screening and HCC surveillance.[1]

[1]

Who gets it — and why only some get sick

MASLD is the commonest chronic liver disease in the world. A meta-analysis of 86 studies puts global adult prevalence around 25 to 30 percent; in type 2 diabetes and obesity it climbs to 56 to over 70 percent, tracking the metabolic syndrome pandemic.[8] MASLD is now a leading indication for transplant and a leading cause of HCC in many countries — and rising everywhere.

ALD depends on dose and duration — but dose alone does not explain it. Only about 10 to 20 percent of heavy drinkers ever develop cirrhosis, which tells you host modifiers matter more than the bottle. The classic risk stack:[1]

• Quantity and pattern — risk climbs above about 30 g/day in women and 50 g/day in men over years; bingeing layers on extra risk.
• Female sex — women cirrhose at lower intake and after shorter exposure, because they carry less gastric alcohol dehydrogenase and a smaller volume of distribution.
• Genetics — PNPLA3 (rs738409, the I148M variant), TM6SF2 (E167K) and HSD17B13 are shared susceptibility alleles for ALD and MASLD alike; the lucky one is HSD17B13 loss-of-function, which protects.
• Malnutrition and sarcopenia — present in over half of severe AH, and an independent killer.
• Obesity and the metabolic syndrome — synergise with alcohol (the MetALD story); an obese drinker fibroses supra-additively.
• Coexisting viral hepatitis (HCV, HBV) — accelerates fibrosis; HCV is itself steatogenic (core protein).
• Smoking — independent modifier.[1]

MASLD risk factors are metabolic, full stop: visceral obesity, type 2 diabetes, metabolic syndrome, dyslipidaemia, hypothyroidism, polycystic ovary syndrome, obstructive sleep apnoea, hypopituitarism.[2]

The classic trap: lean MASLD. About 10 percent of all MASLD hides behind a normal BMI — commoner in Asian populations, driven by visceral fat, sarcopenia, fructose and PNPLA3. It fibroses faster per unit of hepatic fat. A normal weight does not exclude the diagnosis; if anything it lowers your guard and costs the patient a year.[2][10]

Two routes, one cell — the stellate convergence

Both diseases enter the same downstream cascade through different molecular doors. Learn both doors and the management logic writes itself: remove the driver early and the disease regresses; let it run and stellate-cell fibrosis becomes irreversible.[1]

The alcohol door — ethanol to acetaldehyde to the stellate cell

1. Ethanol metabolism. Cytosolic alcohol dehydrogenase (ADH) oxidises ethanol to the highly toxic acetaldehyde; mitochondrial aldehyde dehydrogenase (ALDH2) then clears acetaldehyde to acetate. In chronic drinkers a minor pathway — microsomal CYP2E1 — gets induced and starts pumping out reactive oxygen species (ROS). This is where chronic injury lives.[1]
2. The redox shift drives the fat. Both ADH and ALDH2 convert NAD+ to NADH, so a heavy drinker runs a high NADH:NAD+ ratio. That ratio blocks beta-oxidation and diverts metabolism toward triglyceride synthesis — the biochemistry of alcoholic steatosis in one line.
3. Acetaldehyde makes adducts. Acetaldehyde binds proteins and DNA, generating neoantigens that recruit immune injury; lipid peroxidation (malondialdehyde, 4-HNE) shreds membranes.
4. The gut–liver axis lights the fire. Alcohol loosens intestinal tight junctions, letting lipopolysaccharide (LPS, endotoxin) leak into the portal blood. LPS binds TLR4/CD14 on Kupffer cells, flips on NF-kB, and releases TNF-alpha, IL-1, IL-6 and TGF-beta. TNF-alpha kills hepatocytes; TGF-beta is the master switch for stellate cell activation.
5. Stellate cell activation — the convergent step. The hepatic stellate cell (HSC, Ito cell) is a vitamin-A-storing pericyte lying quiet in the space of Disse. Injured hepatocytes, Kupffer cells and platelets release TGF-beta and PDGF, which transdifferentiate the HSC into an alpha-smooth-muscle-actin-positive myofibroblast. That myofibroblast lays down type I and III collagen, secretes TIMPs (which stop anyone clearing the matrix), and contracts — the structural basis of cirrhosis.[1]

The metabolic door — insulin resistance, lipotoxicity, the same stellate cell

The old "two-hit" hypothesis (Day and James) is dead. It is now a multiple-parallel-hit model:[10]

1. Insulin resistance and lipotoxicity. Peripheral (adipose) insulin resistance drives unregulated lipolysis, flooding the liver with free fatty acids (FFA). At the same time hyperinsulinaemia switches on SREBP-1c and hyperglycaemia switches on ChREBP, both driving de novo lipogenesis. VLDL export cannot keep up; triglyceride accumulates as steatosis.
2. The toxic lipid species. Not triglyceride itself — triglyceride is relatively inert storage. The killers are saturated FFAs (palmitate), ceramides, diacylglycerol and lysophosphatidylcholine. They trigger endoplasmic reticulum stress, the unfolded protein response, mitochondrial dysfunction with ROS, and hepatocyte apoptosis — the histology you read as ballooning degeneration.[10]
3. Inflammation and cell death. Dying hepatocytes release damage-associated molecular patterns (DAMPs) that activate Kupffer cells and recruit neutrophils and monocytes. That is the histological signature of steatohepatitis.
4. The convergent step — same stellate cell, same signals. The same TGF-beta and PDGF that drive fibrosis in ALD drive it in MASH. PNPLA3 and TM6SF2 tune lipid handling and susceptibility; HSD17B13 loss-of-function protects here too.
5. Progression and the HCC twist. Simple steatosis is benign and reversible in most. MASH with F3 to F4 fibrosis progresses to cirrhosis in a real fraction and carries a markedly elevated HCC risk. The twist: MASLD can cause HCC even without established cirrhosis — unique among chronic liver diseases, and the reason surveillance is messy.[10]

Everyone forgets: the stellate cell is the final common pathway for every chronic liver disease you will ever see — alcohol, MASLD, viral, biliary. Understand its activation and you understand fibrosis.[1]

[1]

What walks through the door

Both diseases hide for years. Most patients are picked up on incidentally abnormal LFTs, an echogenic ("bright") liver on ultrasound, or hepatomegaly at a routine exam — not by symptoms. What you see at the bedside depends entirely on the stage.[1]

Early, compensated disease

• MASLD is usually an incidental finding. The patient may mention fatigue and a dull right-upper-quadrant fullness, but most feel entirely well; hepatomegaly is common. Look past the liver: central obesity, type 2 diabetes, hypertension, dyslipidaemia are almost always louder than any hepatic complaint.
• Alcohol-related fatty liver is asymptomatic — perhaps hepatomegaly, a raised GGT, and the stigmata of chronic drinking.[1]

Alcoholic hepatitis — the severe inflammatory syndrome

This is the 3am presentation. Rapid, deep jaundice in a heavy drinker, with anorexia, nausea, abdominal pain and tender hepatomegaly, plus fever and a leucocytosis that mimic sepsis (and that you must actively prove is not sepsis before you reach for steroids). Severe disease brings asterixis, encephalopathy, ascites and coagulopathy.[1]

Decompensated cirrhosis (either aetiology)

The four horsemen: jaundice, ascites, hepatic encephalopathy, variceal haemorrhage. Add the chronic stigmata — spider naevi, palmar erythema, gynaecomastia, testicular atrophy, parotid enlargement, Dupuytren's contracture, caput medusae, asterixis, sarcopenic wasting — and the diagnosis is at the foot of the bed before you shake hands.[1]

The examiner's favourites — atypical presentations

• The elderly patient whose first sign is ascites — advanced "silent" MASLD presenting late; BMI may even read normal (sarcopenic).
• The diabetic with "cryptogenic" cirrhosis — "burnt-out" MASH, where steatosis vanishes once fibrosis destroys fat storage. The clue is the metabolic history, not the biopsy.
• Lean MASLD — normal BMI, visceral adiposity, genetic susceptibility; missed because you assumed BMI excluded it.
• Pregnancy — MASLD overlaps gestational diabetes; AH in pregnancy is rare but savage.
• The HIV-coinfected patient — MASLD accelerated by antiretrovirals and metabolic syndrome; decompensates fast.
• Acute alcoholic hepatitis masquerading as sepsis or biliary obstruction — fever, leucocytosis, RUQ pain and jaundice will send the unwary down the wrong pathway. Everyone reaches for antibiotics. That is how you delay the steroids.[1]

Differential diagnosis — the other yellow livers

When you see steatosis or steatohepatitis, the examiner wants the differential with one discriminator per row. Memorise the table — and remember the single most tested point: AST over ALT favours alcohol, ALT over AST favours MASLD, but the ratio flips to over 1 in any cirrhosis, so it is useless late.[1][2]

"Bright liver" on ultrasound is not synonymous with steatosis. The differential of an echogenic liver also includes diffuse fibrosis (cirrhosis), glycogen storage disease, chemotherapy effect, and rarely Wilson's disease. Do not anchor on fat just because the ultrasound said so.[2]

The bedside — history, hands, and the withdrawal clock

Six things, in order, at every bedside. Miss any one and you have mis-assessed the patient.[1]

1. Take a structured alcohol history. Use the AUDIT (10 items) or AUDIT-C (3 items); quantify intake in grams or units per week; document the pattern (daily vs binge); screen for dependence with CAGE (Cut-down, Annoyed, Guilty, Eye-opener). A vague "he drinks a lot" is a fail.
2. Examine for stigmata of chronic liver disease. Jaundice, palmar erythema, spider naevi, parotid enlargement, gynaecomastia, testicular atrophy, Dupuytren's contracture; then the decompensation signs — ascites (shifting dullness, fluid thrill), splenomegaly, caput medusae, asterixis (the liver flap).
3. Grade encephalopathy on the West Haven scale. I — subtle confusion, inverted sleep, asterixis; II — lethargy, disorientation, obvious asterixis; III — somnolent but rousable, marked confusion; IV — coma. Bedside Trail-Making Test B and connect-the-numbers catch minimal encephalopathy you would otherwise miss.
4. Anthropometry and metabolic screen. BMI and waist circumference (South Asian cut-offs: men over 90 cm, women over 80 cm); blood pressure; screen for metabolic syndrome (NCEP ATP III — 3 of 5: waist, BP, triglycerides, HDL, fasting glucose).
5. Assess withdrawal risk with CIWA-Ar. Withdrawal can complicate any AH admission and is dangerous in its own right — seizure, delirium tremens, death. Score it before it scores you.
6. Assess malnutrition and sarcopenia with Subjective Global Assessment (SGA) and grip strength. Present in over half of severe AH, and an independent predictor of mortality — treat it as a vital sign.[1]

[1]

Investigations — the scores that decide

Bloods first, scores second, biopsy only when it changes a decision. The investigations exist to answer three questions: what is the driver, how advanced is the fibrosis, and (in AH) how sick is the patient today.[1]

Blood tests

Liver function tests — read the pattern, not the number.[1]

• Alcoholic hepatitis pattern: AST over ALT (ratio over 2), both typically under 300 U/L; GGT disproportionately high; bilirubin elevated out of proportion to the modest transaminitis; macrocytosis (MCV over 100 fL); low platelets (portal hypertension plus a direct alcohol effect). Trap: the ratio reverses to over 1 in advanced cirrhosis of any cause, so do not over-read it late.
• MASLD pattern: mild to moderate ALT elevation, ALT usually greater than AST; GGT raised. MASLD is the commonest cause of chronically "abnormal LFTs" with a negative standard work-up. Remember: aminotransferases do not correlate with histological severity and may be entirely normal in advanced fibrosis — a normal ALT does not exclude F4.[1]

Aetiological and severity panel. Full blood count (macrocytosis, thrombocytopenia); coagulation (INR — the single best marker of hepatic synthetic function); albumin; glucose; HbA1c; lipid profile; renal function; viral serology (HBsAg, anti-HCV); ferritin and transferrin saturation; caeruloplasmin if under 40; immunoglobulins and autoantibodies (ANA, SMA, LKM); alpha-1 antitrypsin; pregnancy test in women of childbearing age.[1]

Non-invasive fibrosis scores (reproduced verbatim)

FIB-4 index (Sterling, 2006) — the first-line triage tool in primary care and diabetes clinics:[7]

FIB-4 = (Age in years x AST in U/L) / (Platelets in 10⁹/L x square root of ALT in U/L)

Under 1.3 = low risk (rules out advanced fibrosis); over 2.67 = high risk. Use 3.48 (not 2.67) in patients over 65, in whom the test is less specific.[1]

NAFLD Fibrosis Score (NFS) — adds age, BMI, hyperglycaemia, AST/ALT ratio, platelets and albumin. A score below minus 1.455 = low risk; over 0.676 = high risk.[1]

Imaging

• Ultrasound — a diffusely echogenic ("bright") liver supports steatosis but cannot see fat under about 20 percent, cannot quantify it, and cannot stage fibrosis.
• MRI-derived proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE) — the most sensitive non-invasive methods, but costly and not first-line.
• Transient elastography (FibroScan) — measures liver stiffness: over 8 to 10 kPa suggests significant fibrosis (F2 or more); over 12 to 15 kPa suggests advanced fibrosis or cirrhosis. The controlled attenuation parameter (CAP) on the same probe quantifies steatosis.
• CT — may show a hypodense liver; not a screening tool.[1]

Liver biopsy — the gold standard, with caveats

Biopsy is the reference standard but is not required for diagnosis in the typical MASLD or ALD case. Reach for it when the diagnosis is uncertain (rule out autoimmune, DILI, Wilson's), staging is required in those flagged high-risk by FIB-4, NFS or FibroScan, or you are about to commit to pharmacotherapy (e.g. resmetirom, approved for F2 to F3 MASH). Histology is scored by NAS (NAFLD Activity Score) or SAF (Steatosis-Activity-Fibrosis); look for macrovesicular steatosis, hepatocyte ballooning, lobular inflammation, Mallory–Denk bodies and perisinusoidal ("chicken-wire") fibrosis.[1][10]

Prognostic scores (reproduced verbatim)

Maddrey Discriminant Function (Maddrey DF, 1978) — the original and still standard severity metric for AH:[5]

Maddrey DF = 4.6 x (patient's prothrombin time in seconds − control prothrombin time) + serum total bilirubin in mg/dL

32 or more = severe alcoholic hepatitis — the threshold to consider corticosteroids, after you have excluded infection and GI bleed.[1]

Lille model (Louvet, 2007) — the day-7 steroid-response score:[4]

Calculated from age, albumin, evolution of bilirubin from day 0 to day 7, renal function, prothrombin time and baseline bilirubin. A Lille score over 0.45 defines non-response to corticosteroids — treatment is futile, stop it, and move to transplant assessment in selected patients.[1]

MELD / MELD-Na — bilirubin, INR, creatinine and sodium; predicts 90-day mortality and governs transplant listing. MELD over 21 is the threshold for transplant referral in severe AH.[1]

ABIC (Age-Bilirubin-INR-Creatinine) and GAHS (Glasgow Alcoholic Hepatitis Score) — alternative prognostic scores for the specialist who wants a second opinion.[1]

Resuscitation — the first hours

Severe alcoholic hepatitis and acute decompensation are medical emergencies. Run the bundle in order, and do not skip steps to reach the steroids faster.[1]

1. ABCDE. Secure the airway (intubate for grade III to IV encephalopathy); oxygen if hypoxic; two large-bore cannulae; group and save; treat hypotension with albumin (1 g/kg, max 100 g) or balanced crystalloid.
2. Exclude and treat infection and GI bleed BEFORE corticosteroids. Cultures (blood, urine, ascitic); chest X-ray; ascitic tap for cell count (SBP if neutrophils over 250/mm³); upper-GI endoscopy if any sign of bleeding. Steroids are contraindicated in uncontrolled sepsis or active GI haemorrhage — giving them is how you kill the patient.[1]
3. Correct hypoglycaemia, electrolytes and acid–base. Watch potassium, magnesium and phosphate — phosphate bottoms out with refeeding.
4. Thiamine BEFORE glucose. Thiamine 100 mg IV/PO daily for 3 to 5 days (some centres use 500 mg IV three times daily for 2 to 3 days in severe deficiency), always given before any glucose load to prevent Wernicke encephalopathy. Non-negotiable.[1]
5. Manage alcohol withdrawal. A symptom-triggered benzodiazepine regimen guided by CIWA-Ar: chlordiazepoxide PO (typically 15 to 30 mg QDS, reducing over 7 to 10 days), switching to lorazepam in severe liver failure (no oxidative hepatic metabolism, safer in renal impairment). Avoid heavy sedation in encephalopathy.
6. Nutrition from day 1. Enteral high-protein, high-energy feeding: 35 kcal/kg/day, 1.2 to 1.5 g/kg/day protein. Do not restrict protein — it does not worsen encephalopathy. Malnutrition drives mortality as hard as any drug.
7. Specific emergencies — acute variceal bleed (terlipressin plus endoscopic band ligation plus antibiotics; transfuse to haemoglobin 70 to 80 g/L); hepatic encephalopathy (lactulose plus rifaximin); hepatorenal syndrome (albumin plus terlipressin).[1]

Definitive therapy — turn off the tap

Alcohol-related liver disease

The cornerstone is abstinence — full stop. Complete, sustained abstinence is the single most effective intervention at every stage of ALD: it halts and often partially reverses fibrosis, and dramatically improves survival. Everything else is adjunct.[1]

Severe alcoholic hepatitis — corticosteroids (after you have excluded sepsis and GI bleed). For Maddrey DF 32 or more (or MELD over 21, or GAHS over 9):[1]

Prednisolone 40 mg PO once daily for 28 days (or methylprednisolone 32 mg IV if oral is not tolerated), then taper.[1]

Assess response at day 7 with the Lille score. Over 0.45 = non-response = stop steroids (futile) and move to early transplant assessment.[4]

The evidence — STOPAH (Thursz, NEJM 2015): prednisolone improved 28-day mortality in severe AH; pentoxifylline had no benefit; neither improved 90-day or 1-year mortality. This is the trial that settled steroids as standard and demoted pentoxifylline.[3]

N-acetylcysteine (NAC) as adjunct. Added to prednisolone, NAC cuts infection and improves 1-month (and possibly 6-month) mortality; many units add it routinely.[1]

Pentoxifylline (400 mg TDS) is a weak second-line agent for when steroids are contraindicated. It has no STOPAH benefit as monotherapy — do not reach for it first.[1]

Addiction and relapse-prevention pharmacotherapy (start once liver function stabilises; avoid in acute liver failure): naltrexone 50 mg PO daily (opioid antagonist) and acamprosate 666 mg PO TDS (GABA/glutamate modulator); avoid disulfiram in significant liver disease. Pair the drug with psychosocial support — motivational interviewing, structured counselling, mutual-aid groups. The prescription without the programme relapses.[1]

MASLD / MASH

Step 1 — Lifestyle is the foundation, not the preamble. Weight loss of 7 to 10 percent of body weight: 3 to 5 percent clears steatosis; 7 to 10 percent resolves steatohepatitis; over 10 percent can regress fibrosis. A Mediterranean diet (low refined carbohydrate and fructose, high monounsaturated fat), 150 minutes per week of aerobic plus resistance exercise, and alcohol avoidance underpin every drug below.[2]

Step 2 — Treat the metabolic comorbidities. Optimise type 2 diabetes (metformin does nothing for the liver — prefer agents that do: pioglitazone, GLP-1 agonists); treat dyslipidaemia — and here is the trap everyone falls into: never withhold statins. Statins are safe in chronic liver disease and cut cardiovascular mortality, the leading cause of death in MASLD. The liver will not kill most of these patients; the myocardium will. Treat the blood pressure too.[1]

Step 3 — Pharmacotherapy for F2 to F3 MASH (consider biopsy first).[1]

Bariatric or metabolic surgery is recommended for obesity (BMI over 35 with comorbidity, or over 40) and improves MASLD histology; established cirrhosis needs specialist assessment first (decompensation risk).[1]

Liver transplantation is indicated for decompensated cirrhosis or severe AH non-responders. Most centres still apply the 6-month abstinence rule for ALD, though early transplantation in highly selected severe-AH non-responders is increasingly accepted. MASLD is now a leading transplant indication; recurrence (driven by immunosuppression-related metabolic syndrome) is the long-term worry.[1]

Escalation triggers

• Maddrey 32 or more → start corticosteroids (after excluding infection and GI bleed).
• Lille over 0.45 at day 7 → stop steroids; transplant assessment.
• MELD over 21 → transplant referral.
• New ascites, encephalopathy or variceal bleed → decompensated cirrhosis pathway (see Cirrhosis topic).
• FibroScan over 12 to 15 kPa, or FIB-4 over 3.48 → hepatology referral, variceal screening, HCC surveillance. [1]

Subtypes and special scenarios

• Severe alcoholic hepatitis (Maddrey 32 or more) — corticosteroids after excluding infection and GI bleed; Lille score at day 7 to judge response; early transplant in selected non-responders (some centres waive the 6-month rule for a first AH presentation).
• MASLD in type 2 diabetes — aggressive metabolic control; prefer pioglitazone or a GLP-1 agonist; intensified HCC surveillance if cirrhotic (ultrasound plus AFP every 6 months). Diabetes is the single strongest MASLD predictor — assume every T2DM patient has it until proven otherwise.
• Lean MASLD — lower threshold to biopsy; rule out coeliac disease, DILI and genetic causes (PNPLA3 testing is not routine); push resistance exercise and a Mediterranean diet even at normal BMI, because the risk is visceral fat and sarcopenia, not total mass.
• Cirrhosis from MASLD or ALD — begin 6-monthly HCC surveillance (ultrasound, plus alpha-fetoprotein in many programmes); variceal screening (OGD); vaccinate against HAV, HBV, pneumococcus and annual influenza; avoid hepatotoxic drugs and alcohol.
• Alcoholic hepatitis in pregnancy — rare; supportive care; weigh corticosteroid benefit against fetal risk; multidisciplinary with obstetrics and hepatology.
• Recovery and relapse prevention after AH — structured addiction care; naltrexone or acamprosate once acute liver failure is excluded; address housing, nutrition and mental health — the bottle is usually a symptom, not the disease.
• Paediatric or adolescent MASLD — rising with childhood obesity; lifestyle first (fructose reduction, family-based behavioural intervention); vitamin E has paediatric RCT evidence; pioglitazone is studied in children.[1]

Complications — and the pitfalls that cost marks and lives

The complications are the complications of cirrhosis. Once fibrosis reaches F4, both diseases generate the same sequelae: portal hypertension (ascites, spontaneous bacterial peritonitis, variceal haemorrhage), hepatocellular carcinoma, hepatopulmonary syndrome, portopulmonary hypertension, hepatorenal syndrome, hepatic encephalopathy, sarcopenia, and sepsis.[1][2]

The HCC wrinkle. MASLD is now a leading cause of HCC in many countries, and — uniquely — HCC can arise in MASLD even without established cirrhosis, which complicates surveillance. The cirrhotic recommendation (6-monthly ultrasound) is firm; screening the non-cirrhotic MASLD patient is an evolving controversy.[1]

[1]

The named traps, in full:[1]

• Giving corticosteroids without first excluding infection and GI bleed — the cardinal safety check. Steroids are contraindicated in uncontrolled sepsis, GI haemorrhage or hepatorenal syndrome.
• Giving glucose before thiamine in the malnourished alcoholic precipitates Wernicke encephalopathy. Thiamine first, every time.
• Under-treating withdrawal or pain out of a misplaced fear of "rewarding" addiction — undertreated withdrawal is dangerous (seizures, delirium tremens).
• Withholding statins in MASLD — statins are safe in chronic liver disease and cut cardiovascular mortality, the leading cause of death in these patients. The myocardium kills more MASLD patients than the liver does.
• Refeeding syndrome and hypophosphataemia when nutrition restarts in malnourished AH — monitor phosphate, magnesium and potassium daily and replace aggressively.
• Failing to screen for HCC in compensated MASLD or ALD cirrhosis — every cirrhotic patient needs 6-monthly surveillance.
• Assuming normal LFTs exclude advanced fibrosis — aminotransferases correlate poorly with histology in both diseases.[1]

Prognosis — who goes home, who goes to ICU

• Simple steatosis runs a benign course in most and does not progress to cirrhosis; MASH with advanced fibrosis (F3 to F4) carries markedly worse liver-related mortality.
• Severe alcoholic hepatitis carries a 28-day mortality of 20 to 30 percent untreated; corticosteroids cut this by about a third in responders. The ABIC and MELD scores also predict short-term mortality.[1][3]
• The Lille score (over 0.45 at day 7) defines futility — mortality approaches 75 percent at 6 months in non-responders, who should be considered for early transplant.[4]
• Abstinence is the single biggest determinant of long-term survival in ALD; weight loss of 10 percent or more can reverse fibrosis in MASLD.
• Liver transplantation transforms prognosis in selected patients — 5-year survival over 70 percent — but relapse to alcohol (ALD) and recurrence of MASLD (driven by immunosuppression-related metabolic syndrome) are the long-term threats.
• Disposition: stable MASLD — outpatient lifestyle plus 6-monthly monitoring if cirrhotic; severe AH — inpatient hepatology, with ICU for multi-organ failure; any new decompensation — admit.[1]

Special populations

• Pregnancy — MASLD and gestational diabetes overlap; manage with lifestyle and glycaemic control; AH in pregnancy is rare but severe and mandates a multidisciplinary approach. Avoid statins and pioglitazone in pregnancy (teratogenicity and unknown fetal risk).
• Elderly — sarcopenic MASLD: push resistance exercise and adequate protein; high prevalence of polypharmacy causing DILI masquerading as MASLD; use age-adjusted FIB-4 cut-offs (over 2.67 becomes over 3.48) to limit false positives.
• Type 2 diabetes — MASLD prevalence 56 to 70 percent; intensify metabolic control; GLP-1 agonist or pioglitazone preferred; aggressive HCC surveillance if cirrhotic; the FIB-4-first strategy is recommended for every diabetic.
• HIV coinfection — MASLD accelerated by combination antiretroviral therapy and metabolic syndrome; screen for advanced fibrosis with FIB-4 and FibroScan.
• Post-bariatric surgery — MASLD usually improves with weight loss, but rapid weight loss can rarely precipitate steatohepatitis; AASLD recommends monitoring.
• Children and adolescents — rising with the obesity epidemic; lifestyle first; vitamin E has paediatric RCT evidence; specialist paediatric hepatology referral.[1]

The landmark trials — and the regional deltas

Know these by name and result. They come up in viva as "tell me the trial that established steroids in alcoholic hepatitis."[1]

• STOPAH (Thursz, NEJM 2015) — the largest RCT in severe AH: prednisolone improved 28-day mortality; pentoxifylline had no benefit; neither improved 90-day or 1-year mortality. Settled steroids as standard, demoted pentoxifylline to second-line.[3]
• Louvet Lille model (Hepatology 2007) — the day-7 response score that defines futility of corticosteroids and triggers transplant assessment.[4]
• Maddrey Discriminant Function (Gastroenterology 1978) — the original and still standard severity metric for AH (32 or more = severe).[5]
• Resmetirom MAESTRO-NASH (Harrison, NEJM 2024) — the first drug to demonstrate MASH resolution and fibrosis improvement in a phase 3 RCT; FDA-approved March 2024 as the first MASH-specific pharmacotherapy.[6]
• PIVENS (Sanyal, NEJM 2010) — vitamin E improved histology in non-diabetic NASH; pioglitazone fell just short of the primary endpoint.[9]
• Sterling FIB-4 (Hepatology 2006) — established the FIB-4 index as the first-line non-invasive fibrosis triage tool.[7]
• Younossi global epidemiology (Hepatology 2016, updated 2023) — quantified the global MASLD burden (about 25 percent of adults).[8]
• Rinella nomenclature consensus (Journal of Hepatology 2023) — NAFLD to MASLD, NASH to MASH, and the new MetALD category.[2]

Guidelines and the regional deltas:[1]

• AASLD 2023 Practice Guidance (US) — MASLD and alcohol-associated liver disease; FIB-4-first triage, FibroScan for the indeterminate, resmetirom for F2 to F3 MASH.
• EASL Clinical Practice Guidelines (Europe) — alcohol-related and MASLD; emphasise abstinence programmes and lifestyle respectively.
• NICE NG49 (UK) — NAFLD assessment and management; FibroScan in those at risk of advanced fibrosis.
• INASL or ICMR Indian consensus — emphasises lean MASLD, lower Asian BMI cut-offs (over 23 kg/m²), T2DM screening, and a frugal-diet public-health approach.
• Open controversies: who to screen for HCC in MASLD (cirrhotic — firm; select non-cirrhotic high-risk — evolving); whether to screen the whole T2DM population with FibroScan; the cost-effectiveness of resmetirom; and the 6-month abstinence rule for transplant listing, increasingly relaxed for selected severe AH. [1]

Ward-round test

Stem 1. A 50-year-old man, chronic heavy drinker, presents with deep jaundice, AST 240, ALT 80, bilirubin 300, INR 2.3, MCV 108. Maddrey DF calculates to 48. What is the next drug, and what must you exclude first?[1]

Answer

Prednisolone 40 mg PO daily for 28 days — but only after excluding sepsis (cultures, ascitic tap) and GI bleed (endoscopy). Then reassess at day 7 with the Lille score; over 0.45 means stop and refer for transplant.[4]

Stem 2. A 54-year-old woman with type 2 diabetes and a BMI of 33 has a "bright liver" on ultrasound; FIB-4 is 1.8, FibroScan 9.5 kPa. What is the diagnosis, and what is the first intervention?[2]

Answer

MASLD with indeterminate-to-significant fibrosis (F2 or more) — refer for hepatology assessment and likely biopsy. First intervention: 7 to 10 percent weight loss plus metabolic control. Do not withhold her statin — cardiovascular disease is her leading killer.[6]

Stem 3. Your malnourished alcoholic patient needs a dextrose drip for hypoglycaemia. What do you give first, and why?[1]

Answer

Thiamine before glucose, every time — 100 mg IV/PO daily for 3 to 5 days — to prevent Wernicke encephalopathy. Glucose first precipitates irreversible brain injury in the thiamine-depleted patient.[1]

Stem 4. A 45-year-old with biopsy-proven F2 to F3 MASH has lost only 3 percent of body weight despite counselling. What pharmacotherapy is now first-line?[6]

Answer

Resmetirom 80 mg PO daily (uptitrate to 100 mg after 1 month) — the THR-beta agonist, the first FDA-approved MASH drug (2024, MAESTRO-NASH). Pioglitazone or a GLP-1 agonist are alternatives, especially with T2DM.[6]

Exam pearls

• AST:ALT over 2 with both under 300 = alcoholic hepatitis; AST:ALT under 1 with ALT predominant = MASLD; the ratio reverses to over 1 in any cirrhosis, so it is unreliable in advanced disease.
• Maddrey DF = 4.6 x (PT − control PT) + total bilirubin (mg/dL); 32 or more = severe.
• Lille over 0.45 at day 7 = stop steroids (futile).
• NAFLD was renamed MASLD (2023); NASH renamed MASH — the diagnostic anchor is metabolic dysfunction, not the absence of alcohol.
• Steatosis shows on ultrasound only when fat exceeds 20 percent; MRI-PDFF is the most sensitive imaging; FibroScan for stiffness (F2 or more over 8 kPa, cirrhosis over 12 to 15 kPa).
• FIB-4 = (Age x AST)/(Platelets x square root of ALT); under 1.3 rules out advanced fibrosis; over 2.67 (over 3.48 in over-65s) rules in.
• Resmetirom (THR-beta agonist) is the first FDA-approved MASH drug (2024).
• Weight loss 7 to 10 percent resolves MASH; over 10 percent regresses fibrosis.
• The hepatic stellate cell (Ito cell) is the key fibrogenic cell; activated by TGF-beta and PDGF.
• Both diseases converge on the SAME pathway: steatosis to steatohepatitis to fibrosis to cirrhosis to HCC.
• Naltrexone and acamprosate for relapse prevention; avoid disulfiram and naltrexone in severe liver failure.
• Give thiamine BEFORE glucose to prevent Wernicke encephalopathy in the malnourished alcoholic.
• Statins are SAFE in MASLD — do not withhold; cardiovascular disease is the leading cause of death.
• Pentoxifylline has NO benefit in the STOPAH trial — second-line only.[1]

Exam application bank (NEET-PG / INICET)

One-line answer

Alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) are the two leading causes of chronic liver disease worldwide. Both follow the same histological spectrum — steatosis to steatohepatitis to fibrosis to cirrhosis (and hepatocellular carcinoma) — driven by different insults (alcohol versus obesity, type 2 diabetes and metabolic syndrome). Alcoholic hepatitis is the severe inflammatory form: AST greater than ALT (ratio over 2), both under 300, with jaundice and a high MCV, graded by the Maddrey Discriminant Function (32 or more is severe) and MELD. Management centres on abstinence and addiction care for alcohol-related disease (with corticosteroids for severe alcoholic hepatitis, response assessed by the Lille score at day 7), and weight loss of 7 to 10 percent, metabolic control and emerging pharmacotherapy (pioglitazone, GLP-1 agonists, resmetirom) for MASLD.[1]

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and the first treatment step, with dose and route if drug therapy is standard.[1]

Stem 2 — Unstable or complicated. List the red flags that force immediate resuscitation, theatre, ICU, antidote or reperfusion — and what you do in the first 15 minutes.[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change.[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each.[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU, ICU or theatre, and what follow-up is mandatory.[1]

Rapid viva checklist

1. Definition and classification
2. Pathophysiology chain
3. Bedside signs and criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline or trial name if classic
10. Three exam traps[1]

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Alcoholic and MASLD Liver Disease.[1]

References

1. [1]O'Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease Am J Gastroenterol, 2010.PMID 19904248
2. [2]Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature J Hepatol, 2023.PMID 37364790
3. [3]Thursz MR, Forrest EH, Ryder S Prednisolone or Pentoxifylline for Alcoholic Hepatitis N Engl J Med, 2015.PMID 26176387
4. [4]Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids Hepatology, 2007.PMID 17518367
5. [5]Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis Gastroenterology, 1978.PMID 352788
6. [6]Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis N Engl J Med, 2024.PMID 38324483
7. [7]Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection Hepatology, 2006.PMID 16729309
8. [8]Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes Hepatology, 2016.PMID 26707365
9. [9]Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med, 2010.PMID 20427778
10. [10]Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis Gastroenterology, 2016.PMID 26928243